Hypoesthesia

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Tuesday, March 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone

Retrieved on: 
Monday, March 25, 2024
ABC, Hypoesthesia, Patient, Education, Foot, Bunion, Chronic pain, Quality of life, Life, Surgeon, Woman, Arthritis, Radio, Diving, Pain, Recurrence, Swelling, Parent

PONTE VEDRA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that 100,000 patients have been treated with its patented Lapiplasty® 3D Bunion Correction® System.1 This milestone coincides with the first-ever National Bunion Day in the United States, which is being sponsored by Treace on April 16, 2024, and the launch of its new patient education and brand awareness campaign.

Key Points: 
  • “Achieving this important milestone is a testament to the tireless efforts of our team members and the trust of our surgeon customers and patients, all of whom have made our journey possible,” said John T. Treace, CEO and Founder of Treace.
  • “Since our initial surgical cases in 2015, Treace has been committed to educating people about surgical options that can provide lasting relief from bunion pain through our innovative procedures that are designed to minimize recovery time, reduce recurrence rates, and improve patient outcomes.
  • Today the Company also unveiled its latest campaign to continue to drive patient education and awareness of its Lapiplasty® Procedure.
  • Treace will premiere the “Future You” commercial on the finale of “The Bachelor” TV show on March 25, 2024 at 8:00 p.m. Eastern Time on the ABC network.

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Retrieved on: 
Tuesday, March 5, 2024
Spleen, Liver, Bangladesh Technical Education Board, Autoimmune disease, NIH, Physician, Extrapyramidal system, Weight loss, Dizziness, AL amyloidosis, Amyloidosis, Diagnosis, Joint, Hypoesthesia, Fatigue, Patient, Heart, Tissue, Mortality

LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new AL Amyloidosis awareness campaign Be Proactive in AL™.

Key Points: 
  • LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new AL Amyloidosis awareness campaign Be Proactive in AL™.
  • The campaign seeks to increase awareness about the critical need to recognize and diagnose AL Amyloidosis early, while also educating AL Amyloidosis patients about available treatment options.
  • AL amyloidosis is a life-threatening immunological disorder in which an abnormal protein called amyloid builds up in tissues and organs.
  • “Today, it is common for AL Amyloidosis patients to see 3 or 4 different physicians and wait months to years before being definitively diagnosed with AL amyloidosis,” said Dena Heath, Amyloidosis Research Consortium Board Secretary and Facilitator, Northern California Amyloidosis Support Group.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
Tuesday, March 5, 2024
Senior, Tenderness, Infection, Dizziness, AbbVie, XC, Lidocaine, Swelling, Exercise, Skin, Pregnancy, History, Cyst, Red, HIV/AIDS, Trial of the century, Allergy, Social media, Incidence, Neck, Dermatology, Aspirin, Pain, Forehead, Stroke, Hyaluronic acid, Pimple, Pigment, Ibuprofen, Scar, Rash, Anaphylaxis, Chin, Learning, Weakness, Safety, Filler (linguistics), DSM-IV codes, Hypoesthesia, Clinical trial, Paratriathlon, Bleeding, Face, Jaw, ABBV, Injection, Bruise, AMI, Inflammation, FDA, TSR, U.S. FDA, Confusion, Risk, Steroid, Patient, Tell, Wound, Gram, HIV, Cheek

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024
NMOSD, Social media, Hellwig, Nervous system, Alzheimer's disease, MD, Ofatumumab, Stroke, German, Pregnancy, Life, Risk, Annual general meeting, Multiple sclerosis, DSM-IV codes, AAN, Health, Migraine, Parkinson's disease, Hypoesthesia, Fatigue, Ruhr University Bochum, Mother, Paresthesia, Infant, Concussion, Spinal cord, Breast milk, Epilepsy, Sclerosis, Disease, Child, Rituximab, Natalizumab, Optic nerve, Brain, Demyelinating disease, Research, Immune system, American Academy, Birth control

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

How Cinesteam® Helps Manage Smells From Diabetic Foot

Retrieved on: 
Thursday, February 29, 2024
Diabetes, Smell, Blood, Diabetic foot, Sensation, Pain, Infection, Foot, Diabetic neuropathy, Ulcer, Blister, Mayo Clinic, Peripheral neuropathy, Hypoesthesia, Business, Code, Dentistry

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes. The condition can lead to chronic wounds that produce highly unpleasant smells. Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes.
  • Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.
  • The medical condition comes with many health concerns, one of which is commonly referred to as "diabetic foot."
  • Mayo Clinic reports that as much as 50% of those with diabetes can be affected by diabetic neuropathy, opening the doors for diabetic foot to develop.

InventHelp Inventor Develops Specially Designed Pillow (LAX-1603)

Retrieved on: 
Monday, February 12, 2024
Head, Neck, Neck pain, Spine, Multimedia, Suite, Sale, Human, Back pain, Hypoesthesia, Pressure

PITTSBURGH, Feb. 12, 2024 /PRNewswire/ -- "I wanted to create a specially designed pillow to provide optimum support for the head, neck, shoulders, arms, back, lower back, and hips," said an inventor, from Arcadia, Calif., "so I invented the WORLDS GREATEST PILLOW.

Key Points: 
  • PITTSBURGH, Feb. 12, 2024 /PRNewswire/ -- "I wanted to create a specially designed pillow to provide optimum support for the head, neck, shoulders, arms, back, lower back, and hips," said an inventor, from Arcadia, Calif., "so I invented the WORLDS GREATEST PILLOW.
  • I don't believe in one size fits all, so, it is a custom pillow made to fit each individual's size based on weights and heights."
  • The patent-pending creation provides an improved design for a pillow.
  • 22-LAX-1603, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Merck Manuals Details Key Facts to Know About Multiple Sclerosis

Retrieved on: 
Wednesday, February 7, 2024
Hypoesthesia, Leg, Research, Immune system, MD, Patient, Pain, Neurology, Virus, Confusion, Diagnosis, University of Saskatchewan, Hand, College of Medicine, Brain, Editorial, Multiple sclerosis, Risk, Infection, Combustion, University, Face, System, Spinal cord

The cause of MS is unknown, but some studies point to early exposure to certain viruses in triggering the immune system to attack the body's own tissue.

Key Points: 
  • The cause of MS is unknown, but some studies point to early exposure to certain viruses in triggering the immune system to attack the body's own tissue.
  • Individuals without a formal diagnosis may be tempted to ignore their illness, especially if symptoms have waned, says Levin.
  • But he adds it's crucial to work to uncover the cause of symptoms and discuss them with a healthcare professional.
  • Based on the condition and its symptoms, neurologists can guide patients toward the most effective treatments and medications.

CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Retrieved on: 
Monday, January 22, 2024
Senior, Lupus, Paresthesia, Heat, Diabetes, Face, FLX, Blister, Growth, CPT, Epilepsy, Bausch Health, Genital herpes, Breastfeeding, Burns, Hypoesthesia, Glycine mollis, Eyelid, National Medical Products Administration, BHC, NMPA, Medical device

[See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]

Key Points: 
  • [See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]
  • "The approval of Thermage FLX, and the TR-4 return pad, marks a significant milestone for Solta Medical," Thomas J. Appio, Bausch Health Chief Executive Officer, said.
  • "The approval from NMPA means we are able to continue the momentum of the growth of Thermage in China," Jiny Kim, Senior Vice President, Solta Medical, said.
  • Ask your doctor for more information about Thermage FLX and see www.thermage.com for additional details.

German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN

Retrieved on: 
Tuesday, January 23, 2024
OCEAN, Patient, Diabetic neuropathy, DGS, Pain disorder, Registered, CBM, Quality of life, Hypoesthesia, Safety, Observational study, Neuropathic pain, CINP, Pain, Chronic pain, THC, Possible (charity), Pharmaceutical industry

Avextra, the German pharmaceutical company focused on Cannabis-Based Medicines (CBM) and the German Pain Association (DGS), the leading physicians’ society dedicated to chronic pain therapy, jointly announces their collaboration to support patients suffering from Chemotherapy-induced neuropathic pain (CINP).

Key Points: 
  • Avextra, the German pharmaceutical company focused on Cannabis-Based Medicines (CBM) and the German Pain Association (DGS), the leading physicians’ society dedicated to chronic pain therapy, jointly announces their collaboration to support patients suffering from Chemotherapy-induced neuropathic pain (CINP).
  • BENSHEIM, Germany, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce a joint study with the German Pain Association (DGS) focused on Chemotherapy-induced neuropathic pain (CINP).
  • Avextra is proud to collaborate with the German Pain Association (DGS) on their OCEAN study and address the research gap.
  • OCEAN will evaluate a number of factors including pain intensity, pain-related impairments, sleep quality and the phenotypes of neuropathic pain.